Início › Linfoma de Burkitt › Texas
Ensaios clínicos de Linfoma de Burkitt em Texas
24 estudos para Linfoma de Burkitt estão buscando participantes em locais em Texas.
Cidades em Texas
- Houston21 estudos
- Dallas7 estudos
- San Antonio7 estudos
- Austin5 estudos
- Corpus Christi4 estudos
- El Paso4 estudos
- Fort Worth4 estudos
- Lubbock3 estudos
- Killeen3 estudos
Texto oficial do estudo (Inglês)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 10
RecrutandoFase 2
366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Houston Methodist Hospital, Houston
RecrutandoFase 3
Idades de 18 a 39 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecrutandoEstudo observacional
Idades de 0 a 38 · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 7
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
RecrutandoFase 3
Idades 1 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RecrutandoFase 1/2
6 Months – 25 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
RecrutandoFase 1
Idades de 0 a 18 · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 10
RecrutandoFase 2
Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 12
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
RecrutandoFase 2
Idades de 7 a 25 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06137118Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- M D Anderson Cancer Center, Houston
RecrutandoFase 2
Idades 15 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jul. de 2026 · NCT01371630Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Houston
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT07109219Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RecrutandoFase 2
Idades 14 e acima · Todos os sexos · Atualizado em 20 de mai. de 2026 · NCT02877303Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de nov. de 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - St. David's South Austin Medical Center, Austin
- MD Anderson Cancer Center, Houston
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
RecrutandoFase 1/2
Idades de 15 a 50 · Todos os sexos · Atualizado em 9 de set. de 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- The University of Texas M. D. Anderson Cancer Center, Houston
- Methodist Healthcare System, San Antonio
RecrutandoFase 2
Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de mai. de 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de nov. de 2024 · NCT06034275Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.